Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
NNC-4005-0001 in Metabolic Dysfunction Associated Steatohepatitis: NCT07214870 Clinical Landscape Report 2026
18 September 2026
NCT07214870 clinical landscape for Metabolic Dysfunction Associated Steatohepatitis: endpoints, sponsor, phase, geography, readouts, asset context and develo…
9 min read
Anti-EGFR/IL-13R alpha 2 CAR-T cell therapy(Tmunity Therapeutics/University of Pennsylvania) in Recurrent Glioma: NCT07209241 Clinical Landscape Report 2026
18 September 2026
NCT07209241 clinical landscape for Recurrent Glioma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
![Yttrium [90Y] chloride in Recurrent Glioblastoma: NL-OMON61160 Clinical Landscape Report 2026](https://synapse-static-patsnap-com.libproxy1.nus.edu.sg/strapi-static/Blog_cover_13_1a4cebe3b5.jpg)
9 min read
Yttrium [90Y] chloride in Recurrent Glioblastoma: NL-OMON61160 Clinical Landscape Report 2026
18 September 2026
NL-OMON61160 clinical landscape for Recurrent Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Pembrolizumab in Squamous Cell Carcinoma of Head and Neck: NCT07218003 Clinical Landscape Report 2026
18 September 2026
NCT07218003 clinical landscape for Squamous Cell Carcinoma of Head and Neck: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
Ruxolitinib Phosphate in Renal Cell Carcinoma: NCT07219576 Clinical Landscape Report 2026
18 September 2026
NCT07219576 clinical landscape for Renal Cell Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Amisodin in Amyotrophic Lateral Sclerosis: NCT07221240 Clinical Landscape Report 2026
18 September 2026
NCT07221240 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Nivolumab in Microsatellite instability-high colorectal cancer: NCT07223424 Clinical Landscape Report 2026
18 September 2026
NCT07223424 clinical landscape for Microsatellite instability-high colorectal cancer: endpoints, sponsor, phase, geography, readouts, asset context and devel…
9 min read
Terazosin Hydrochloride in Amyotrophic Lateral Sclerosis: NCT07224269 Clinical Landscape Report 2026
18 September 2026
NCT07224269 clinical landscape for Amyotrophic Lateral Sclerosis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tofersen in Amyotrophic Lateral Sclerosis 1: NCT07223723 Clinical Landscape Report 2026
18 September 2026
NCT07223723 clinical landscape for Amyotrophic Lateral Sclerosis 1: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Temozolomide in Diffuse midline glioma, point mutation K27M in histone H3: NCT07223034 Clinical Landscape Report 2026
18 September 2026
NCT07223034 clinical landscape for Diffuse midline glioma, point mutation K27M in histone H3: endpoints, sponsor, phase, geography, readouts, asset context a…
9 min read
Tafasitamab-Cxix in High grade B-cell lymphoma: NCT07225439 Clinical Landscape Report 2026
18 September 2026
NCT07225439 clinical landscape for High grade B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
177Lu-FAPI in Glioblastoma: CTRI/2025/11/097005 Clinical Landscape Report 2026
18 September 2026
CTRI/2025/11/097005 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.